Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Serum levels of TGFβ and VEGF in lung cancer patients and healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004
Expression of MAGE in the induced sputum of lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 595s Year: 2002
Tumor markers in bronchial secretions and serum in patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
The elevation serum napsin A in primary lung adenocarcinoma, compared with CEA Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Elevated serum levels of oxidative stress biomarkers in patients with lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Detection of MAGE-A expression in induced sputum and bronchial lavage fluid of patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 362s Year: 2003
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
Clinical significance of serum osteopontin levels in lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Comparison of tumour markers in induced sputum and serum Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004